| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,305 |
4,140 |
$336K |
| 99051 |
|
8,601 |
6,776 |
$208K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,989 |
1,715 |
$178K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
632 |
534 |
$41K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
586 |
513 |
$36K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,185 |
985 |
$32K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
166 |
148 |
$21K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
481 |
337 |
$15K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
319 |
249 |
$11K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
74 |
55 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
287 |
136 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
51 |
50 |
$3K |
| 87807 |
|
147 |
103 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
129 |
114 |
$2K |
| 94760 |
|
655 |
535 |
$17.11 |